SCHEDULE: Millennium Entities Report Stake in Collegium Pharma

Several entities affiliated with Millennium Management have reported beneficial ownership of over 5% of Collegium Pharmaceutical's common stock.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G.
• This filing indicates their beneficial ownership of Collegium Pharmaceutical, Inc. common stock.
• Integrated Core Strategies (US) LLC beneficially owns 1,769,122 shares, representing 5.4% of the class.
• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each beneficially own 1,820,330 shares, representing 5.6% of the class.
• The filing is made under Rule 13d-1(b), indicating these entities are investment advisers or similar institutions.
• The date of the event requiring this filing is August 17, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without indicating a significant shift in investment strategy or company performance.

Positives

• The filing confirms significant institutional ownership by entities associated with Millennium Management.
• The reporting entities are classified as investment advisers, suggesting professional management of the stake.

Negatives

• The filing does not provide details on the specific investment strategy or rationale behind the ownership stake.
• There is no information regarding the acquisition date or cost basis of the shares.

Risks

• Potential for increased market volatility if these large holders decide to significantly alter their positions.
• Concentration of ownership among a few related entities could influence corporate governance decisions.

Future Outlook

No forward-looking statements or specific future guidance are provided in this Schedule 13G filing.

Management Comments

• The entities disclaim beneficial ownership of securities held by other entities, except to the extent of their pecuniary interest.
• The filing states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes. The reporting by Millennium entities suggests a notable position in the pharmaceutical sector, specifically within Collegium Pharmaceutical's focus areas.

Related Party Transactions

• The filing itself is a joint filing agreement among related entities (Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander), indicating coordinated action regarding the beneficial ownership of Collegium Pharmaceutical stock.

Stakeholder Impact

• Shareholders: May observe increased trading activity or potential influence on stock price due to the significant stake held by these entities.
• Management/Board of Directors: May need to consider the influence of these large, coordinated holders in future corporate decisions.

Next Steps

• Continued monitoring of Collegium Pharmaceutical's performance and any further filings by these reporting entities.
• Potential for these entities to engage in further transactions impacting their ownership stake.

Key Dates

Keywords

Collegium Pharmaceutical, Schedule 13G, Beneficial Ownership, Millennium Management, Integrated Core Strategies, Investment Adviser, Securities Exchange Act